Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12497200 | 0.84 | MAPT (0.53) | MAPTSNCAESR1ESR2PDE4A | |
| SCHEMBL11521584 | 0.79 | HSD17B1 (0.51) | ESR1ESR2PTPN1HSD17B1HSD17B2 | |
| SCHEMBL12937485 | 0.77 | MAPT (0.45) | MAPTSNCAESR1ESR2PDE4A | |
| SCHEMBL12497249 | 0.68 | SNCA (0.54) | MAPTSNCAPDE4APTPN1KDM4E | |
| SCHEMBL28008454 | 0.68 | PDCD1 (0.55) | PDCD1CD274MAPTKDM4EALDH1A1 | |
| SCHEMBL6094201 | 0.68 | TNFRSF1A (0.49) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11519955 | 0.68 | HSD17B1 (0.48) | MAPTESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL23222436 | 0.67 | PDE4A (0.46) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11520829 | 0.66 | ESR1 (0.59) | MAPTESR1ESR2PTPN1ALDH1A1 | |
| SCHEMBL22697440 | 0.65 | PDCD1 (0.51) | PDCD1CD274MAPTPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | AVID RADIOPHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PSEN1, PSEN2, GRN | PDCD1 2440/4885CD274 3622/4885MAPT 4/4885 |
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | PDCD1 2440/4885CD274 3622/4885MAPT 4/4885 |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | SNCA, MAPT, PARK7 | PDCD1 476/4885CD274 2208/4885MAPT 2/4885 |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | SNCA, PARK7, NLN | PDCD1 2289/4885CD274 3767/4885MAPT 15/4885 |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | PDCD1 2440/4885CD274 3622/4885MAPT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.